within Pharmacolibrary.Drugs.ATC.C;

model C01CA01
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.55,
    Cl             = 0.0002666666666666667,
    adminDuration  = 600,
    adminMass      = 10 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.003,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.004166666666666667,
    Tlag           = 600
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>C01CA01</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Etilefrine is a sympathomimetic amine primarily used as a vasopressor for the treatment of hypotension (low blood pressure), particularly orthostatic hypotension. It acts mainly by stimulating alpha- and beta-adrenergic receptors, leading to increased cardiac output and vascular tone. The drug is not widely used today and is approved in a limited number of countries.</p><h4>Pharmacokinetics</h4><p>Estimated pharmacokinetic parameters for healthy adult humans, as there are no definitive peer-reviewed clinical PK models published for etilefrine.</p><h4>References</h4><ol><li><p>Hassen Elshafeey, A, &amp; Moataz El-Dahmy, R (2022). A novel oral medicated jelly for enhancement of etilefrine hydrochloride bioavailability: . <i>Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society</i> 30(10) 1435–1447. DOI:<a href=&quot;https://doi.org/10.1016/j.jsps.2022.07.004&quot;>10.1016/j.jsps.2022.07.004</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/36387345/&quot;>https://pubmed.ncbi.nlm.nih.gov/36387345</a></p></li><li><p>Onishi, H, &amp; Sakata, O (2021). Preparation and evaluation of fast-dissolving films of etilefrine hydrochloride for practical buccal dosing. <i>Pharmaceutical development and technology</i> 26(5) 610–616. DOI:<a href=&quot;https://doi.org/10.1080/10837450.2021.1904260&quot;>10.1080/10837450.2021.1904260</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33736577/&quot;>https://pubmed.ncbi.nlm.nih.gov/33736577</a></p></li><li><p>Sakata, O, &amp; Onishi, H (2020). Preparation of orally fast-dissolving tablets of etilefrine hydrochloride to achieve efficient absorption. <i>Pharmaceutical development and technology</i> 25(9) 1162–1167. DOI:<a href=&quot;https://doi.org/10.1080/10837450.2020.1794000&quot;>10.1080/10837450.2020.1794000</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/32644855/&quot;>https://pubmed.ncbi.nlm.nih.gov/32644855</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end C01CA01;
